BIOCAPTIVA Secures £1.6M Seed Funding for Magnetic Bead Liquid Biopsy Technology
BIOCAPTIVA, a University of Edinburgh spin-out, has raised £1.6 million in seed funding to commercialize its magnetic bead platform for preparing blood samples for liquid biopsy. The funding will support R&D and product expansion following the launch of research-use kits in the US. The patented msX platform captures cell-free DNA directly from whole blood, improving sample quality and enabling automation. The funding round was led by Archangels with participation from other investors, highlighting regional support for biotech innovation.
Theia Market Signal Identification - AI Assisted
BIOCAPTIVA has raised £1.6 million in seed funding to commercialize a magnetic bead platform designed for liquid biopsy sample preparation. The funding will enhance R&D and expand its product range after launching research-use kits in the US.
The msX platform captures cell-free DNA from whole blood, improving extraction processes and facilitating automation. The funding round was led by Archangels, with participation from Old College Capital, BBI, Scottish Enterprise, and EverQuest Capital Partners. This investment emphasizes the potential market impact and growth trajectory for BIOCAPTIVA within the biotechnology sector.
Comments